A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
InMIND
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
3 other identifiers
interventional
654
27 countries
257
Brief Summary
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Apr 2021
Longer than P75 for phase_3
257 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 17, 2020
CompletedFirst Posted
Study publicly available on registry
December 22, 2020
CompletedStudy Start
First participant enrolled
April 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 23, 2024
CompletedResults Posted
Study results publicly available
April 4, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 9, 2028
ExpectedDecember 22, 2025
December 1, 2025
2.9 years
December 17, 2020
February 18, 2025
December 4, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First
PD, positron emission tomography (PET): score 4 (uptake moderately \> liver) or 5 (uptake markedly higher than liver and/or new lesions) for lymph node/extra lymphatic sites with increase in intensity of Baseline uptake and/or new fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma at interim/end-of-treatment assessment; new/recurrent FDG-avid foci in bone marrow; new FDG-avid foci consistent with lymphoma versus other etiology in new lesions. PD, computed tomography (CT): abnormal individual node/lesion with longest diameter (LDi ) \>1.5 centimeters (cm) and increase by ≥50% from the product of the perpendicular diameters (PPD) nadir and increase in LDi or shortest diameter (SDi) from nadir; new/clear progression of preexisting nontarget lesions; new/recurrent splenomegaly and bone marrow involvement; regrowth of previously resolved lesions. New node \>1.5 cm in any axis. New extranodal site \>1.0 cm in any axis; if \<1.0 cm, presence is unequivocal and attributable to lymphoma.
up to approximately 34 months
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First
PD, PET: score 4 (uptake moderately \> liver) or 5 (uptake markedly higher than liver and/or new lesions) for lymph node/extra lymphatic sites with increase in intensity of Baseline uptake and/or new FDG-avid foci consistent with lymphoma at interim/end-of-treatment assessment; new/recurrent FDG-avid foci in bone marrow; new FDG-avid foci consistent with lymphoma versus other etiology in new lesions. PD, CT: abnormal individual node/lesion with LDi \>1.5 cm and increase by ≥50% from the PPD nadir and increase in LDi or SDi from nadir; new/clear progression of preexisting nontarget lesions; new/recurrent splenomegaly and bone marrow involvement; regrowth of previously resolved lesions. New node \>1.5 cm in any axis. New extranodal site \>1.0 cm in any axis; if \<1.0 cm, presence is unequivocal and attributable to lymphoma. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.
up to 2 years
Secondary Outcomes (34)
Overall Population: PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First
up to approximately 34 months
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First
up to 2 years
FDG-avid FL Population: Positron Emission Tomography-Complete Response (PET-CR) Rate by Investigator Assessment, Using the Lugano 2014 Criteria
up to approximately 34 months
FL Population: Overall Survival
up to approximately 34 months
FL Population: Kaplan-Meier Estimates of Overall Survival
up to 2 years
- +29 more secondary outcomes
Study Arms (2)
Arm A : tafasitamab + rituximab + lenalidomide
EXPERIMENTALAdult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)
Arm B : placebo+rituximab+lenalidomide
PLACEBO COMPARATORAdult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)
Interventions
Rituximab will be administered IV on cycles 1 - 5
Lenalidomide will be administered PO for 12 cycles
tafasitamab will be administered IV for 12 cycles
Eligibility Criteria
You may qualify if:
- Histologically confirmed Grade 1, 2, or 3a FL or nodal MZL, splenic MZL, or extra nodal MZL
- Willingness to avoid pregnancy or fathering children
- In the opinion of the investigator, be able and willing to receive adequate mandatory prophylaxis and/or therapy for thromboembolic events (eg, aspirin 70-325 mg daily or low-molecular-weight heparin)
- Previously treated with at least 1 prior systemic anti-CD20 immunotherapy or chemo-immunotherapy
- Documented relapsed, refractory, or PD after treatment with systemic therapy
- ECOG performance status of 0 to 2
You may not qualify if:
- Women who are pregnant or breastfeeding.
- Any histology other than FL and MZL or clinical evidence of transformed lymphoma
- Prior non-hematologic malignancy
- Congestive heart failure
- HCV positivity, chronic HBV infection or history of HIV infection
- Active systemic infection
- CNS lymphoma involvement
- Any systemic anti-lymphoma and/or investigational therapy within 28 days prior to the start of Cycle 1
- Prior use of lenalidomide in combination with rituximab
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (261)
John Muir Health Clinical Research Center
Concord, California, 94520-2266, United States
Marin Cancer Care
Greenbrae, California, 94904, United States
The Oncology Institute of Hope and Innovation
Pasadena, California, 91105, United States
Sharp Memorial Hospital
San Diego, California, 92123, United States
Middlesex Hospital Cancer Center
Middletown, Connecticut, 06457, United States
Smilow Cancer Hospital
New Haven, Connecticut, 06510, United States
Cancer Specialists of North Florida
Jacksonville, Florida, 32256, United States
Brcr Medical Center, Inc
Plantation, Florida, 33322, United States
Asclepes Research Centers
Weeki Wachee, Florida, 34607, United States
Northwest Georgia Oncology Centers,P.C
Marietta, Georgia, 30060, United States
Straub Medical Center
Honolulu, Hawaii, 96813, United States
Des Moines Oncology Research Association
Des Moines, Iowa, 50309, United States
Baptist Health Lexington
Lexington, Kentucky, 40503, United States
Norton Cancer Institute
Louisville, Kentucky, 40207, United States
Tulane University
New Orleans, Louisiana, 70112, United States
University of Maryland-Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
Cancer Center For Blood Disorders
Bethesda, Maryland, 20817, United States
Barbara Ann Karmanos Cancer Hospital
Detroit, Michigan, 48201, United States
Metro-Minnesota Community Oncology Reserch Consortium (Mmcorc)
Saint Louis Park, Minnesota, 55416, United States
Hattiesburg Clinic Hematology
Hattiesburg, Mississippi, 39401, United States
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Nyu Clinical Cancer Center
New York, New York, 10016, United States
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Integris Cancer Institute
Oklahoma City, Oklahoma, 73142, United States
Charleston Hematology Oncology Associates
Charleston, South Carolina, 29414, United States
Prisma Health Upstate
Greenville, South Carolina, 29615, United States
Prairie Lakes Health Care System, Inc.
Watertown, South Dakota, 57201, United States
Texas Oncology-Baylor Charles A. Sammons
Dallas, Texas, 75246, United States
The Center For Cancer and Blood Disorders
Fort Worth, Texas, 76104, United States
Lyndon B Johnson General Hospital
Houston, Texas, 77026, United States
Md Anderson Cancer Center
Houston, Texas, 77030, United States
Renovatio Clinical
Spring, Texas, 77380, United States
Utah Cancer Specialists
Salt Lake City, Utah, 84107, United States
University of Virginia Medical Center
Charlottesville, Virginia, 22908, United States
Vista Oncology Inc Ps
Olympia, Washington, 98506, United States
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
University of Washington-Seattle Cancer Care Alliance
Seattle, Washington, 98109-4405, United States
Northwest Medical Specialties Pllc
Tacoma, Washington, 98405, United States
St George Hospital
Kogarah, New South Wales, 02217, Australia
Liverpool Hospital
Sydney, New South Wales, 02170, Australia
Wollongong Hospital - Illawarra Regional Hospital
Wollongong, New South Wales, 02500, Australia
Gold Coast Hospital
Southport, Queensland, 04215, Australia
Royal Adelaide Hospital
Adelaide, South Australia, 05000, Australia
Flinders Medical Centre
Bedford Park, South Australia, 05042, Australia
The Alfred Hospital
Melbourne, Victoria, 03004, Australia
Northern Hospital
Melbourne, Victoria, 03076, Australia
Western Health
St Albans, Victoria, 03021, Australia
Perth Blood Institute
West Perth, Western Australia, 06005, Australia
Eastern Health
Box Hill, 3128, Australia
Royal Hobart Hospital
Hobart, 07000, Australia
Landeskrankenhaus Universitatsklinikum Graz
Graz, 08036, Austria
Innsbruck University Hospital
Innsbruck, 06020, Austria
Kepler Universitat Klinikum
Linz, 04020, Austria
*Krankenhaus*
Vienna, 01090, Austria
Zna Stuivenberg
Antwerp, 02060, Belgium
A.Z. St.-Jan-Dienst Hematologie
Bruges, 8000, Belgium
Institut Jules Bordet
Brussels, 01000, Belgium
Cliniques Universitaires Ucl Saint-Luc
Brussels, 01200, Belgium
Universitair Ziekenhuis Antwerpen, Dienst Hematologie
Edegem, 2650, Belgium
Ghent University Hospital
Ghent, 09000, Belgium
Universitair Ziekenhuis (Uz) Leuven
Leuven, 03000, Belgium
Centre Hospitalier Universitaire de Liege - Sart Tilman
Liège, 04000, Belgium
AZ Delta
Roeselare, 8800, Belgium
Chu Ucl Namur University Hospital Mont-Godinne
Yvoir, 05530, Belgium
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
British Columbia Cancer Agency
Vancouver, British Columbia, V5Z 1L3, Canada
Queen Elizabeth Ii Health Sciences Centre
Halifax, Nova Scotia, B3H 2Y9, Canada
London Health Sciences Centre
London, Ontario, N6A 5W9, Canada
Hospital Maisonneuve Rosemont
Montreal, Quebec, H1T 2M4, Canada
McGill University Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
Chu de Quebec - Universite Laval (Chul)
Québec, Quebec, G1J 1Z4, Canada
University
Brno, 62500, Czechia
University Hospital Hradec Kralove
Hradec Králové, 50333, Czechia
University Hospital Ostrava
Ostrava, 70800, Czechia
University Hospital Kralovkse Vinohrady
Prague, 10034, Czechia
Vseobecna Fakultni Nemocnice
Prague, 128 08, Czechia
University Hospital Motol
Prague, 15000, Czechia
Aalborg University Hospital
Aalborg, 09000, Denmark
Aarhus University Hospital
Aarhus, 08200, Denmark
Odense University Hospital
Odense, 05000, Denmark
Sjaellands Universitetshospital Naestved
Roskilde, 04000, Denmark
Kuopio University Hospital
Kuopio, 70210, Finland
Oulu University Hospital
Oulu, 90220, Finland
Tampere University Hospital
Tampere, 33520, Finland
Turku University Hospital
Turku, 20520, Finland
Chu Amiens Picardie - Hopital Sud
Amiens, 80054, France
Chu Angers Hotel Dieu Nord
Angers, 49933, France
Groupe Bordeaux Nord Aquitaine Gbna Polycliniques - Polyclinique Bordeaux Nord Aquitaine Pbna
Bordeaux, 33000, France
Centre Hospitalier Universitaire Chu Dijon Bourgogne - Hopital Francois Mitterrand
Dijon, 21000, France
Centre Hospitalier de Versailles - Hopital Andre Mignot
Le Chesnay, 78150, France
CHU Nantes
Nantes, 44093, France
Hospital Saint-Louis Service Oncologie Medicale
Paris, 75010, France
A.P.H. Paris Hopital Cochin
Paris, 75014, France
Hôpital Pitié Salpêtrière
Paris, 75651, France
Centre Hospitalier de Pontoise
Pontoise, 95303, France
Centre Hospitalier Annecy-Genevois
Pringy, 74374, France
Chru Hopitaux de Tours Hospital Bretonneau
Tours, 37044, France
Klinikum St. Marien Amberg
Amberg, 92224, Germany
Klinik Fur Innere Medizin Hamatologie and Onkologie
Berlin, 10967, Germany
Universitatsklinikum Essen
Essen, 45147, Germany
University Clinic Giessen Und Marburg Ukgm
Giessen, 35392, Germany
Universitaetsmedizin Greifswald
Greifswald, 17475, Germany
Statistics and Data Corporation (Sdc)
Landshut, 84036, Germany
Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
Mainz, 55131, Germany
Medizinische Fakultaet Mannheim Der Universitaet Heidelberg
Mannheim, 68167, Germany
Universitatsklinikum Munster
Münster, 48149, Germany
Onkologische Schwerpunktpraxis
Oldenburg, 26121, Germany
Universitarsfrauenklinik Ulm
Ulm, 89081, Germany
Universitaetsklinikum Wuerzburg
Würzburg, 97080, Germany
251 Air Force General Hospital
Athens, 11525, Greece
General Hospital of Athens Laiko
Athens, 11527, Greece
University Hospital of West Attica - Attikon
Athens, 12462, Greece
University General Hospital of Patras
Pátrai, 26504, Greece
Semmelweis Egyetem
Budapest, 01088, Hungary
National Institute of Oncology
Budapest, 01122, Hungary
Debreceni Egyetem Klinikai Kozpon Belgyogy Klinika
Debrecen, 04032, Hungary
Markhot Ferenc Korhaz
Eger, 03300, Hungary
Petz Aladar County Teaching Hospital
Győr, 09024, Hungary
Szabolcs-Szatmar-Bereg Megyei Korhazak Es Egyetemi Oktatokorhaz
Nyíregyháza, 04400, Hungary
University of Szeged
Szeged, 06725, Hungary
Beaumont Hospital
Dublin, D9 V2N0, Ireland
University Hospital Galway
Galway, H91 YR71, Ireland
Ha Emek Medical Center
Afula, 18105, Israel
Soroka
Bear Sheva, Israel
Shamir Medical Center Formerly Assaf Harofeh Medical Center
BEER Yaaqov, 70300, Israel
Wolfson
Holon, 5822012, Israel
Shaare Zedek Mc
Jerusalem, 9103102, Israel
"Laiko" General Hospital of Athens, Hematology of the First Propaedeutic Internal Medicine Clinic
Jerusalem, 91120, Israel
Hadassah
Jerusalem, 91120, Israel
Meir Medical Center
Kfar Saba, 44281, Israel
Rabin Medical Center - Beilinson Hospital
Petah Tikva, 49100, Israel
Sheba Medical Center
Tel Litwinsky, 5265601, Israel
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari
Bari, 70124, Italy
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Brescia, 25123, Italy
Divisione Clinicizzata Di Ematologia
Brescia, 25123, Italy
Fondazione Del Piemonte Per L Oncologia Ircc Candiolo
Candiolo, 10060, Italy
Divisione Clinicizzata Di Ematologia
Catania, 95123, Italy
Presidio Ospedaliero Vito Fazzi
Lecce, 73100, Italy
Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
Milan, 20133, Italy
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, 20162, Italy
Istituto Nazionale Tumori Irccs Fondazione Pascale
Naples, 80131, Italy
Universita Di Napoli Federico Ii
Naples, 80131, Italy
Azienda Ospedaliero Universitaria Maggiore Della Carita Di Novara
Novara, 28100, Italy
Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano
Orbassano, 10043, Italy
Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello
Palermo, 90146, Italy
Fondazione Irccs Policlinico San Matteo
Pavia, 27100, Italy
Ausl Di Placenza Ospedale Guglielmo Da Saliceto
Piacenza, 29100, Italy
Uo Ematologia Univ - Aoup Santa Chiara Pisa
Pisa, 56126, Italy
Ospedale Santa Maria Delle Croci
Ravenna, 48121, Italy
Arcispedale Santa Maria Nuova
Reggio Emilia, 42100, Italy
Ausl Della Romagna
Rimini, 47923, Italy
Universita Degli Studi Di Roma La Sapienza - Umberto I Policlinico Di Roma - Centro Di Ematologia
Roma, 00161, Italy
Ospedale Sant. Eugenio
Rome, 00144, Italy
Irccs Azienda Ospedaliera Universitaria San Martino
San Martino, 16132, Italy
Azienda Ospedaliero Universitaria Citta Della Salute E Della Scienza
Torino, 10126, Italy
Asugi Ospedale Maggiore
Trieste, 34125, Italy
National Hospital Organization Kyushu Cancer Center
Fukuoka, 811-1395, Japan
Chugoku Center Hospital
Fukuyama-shi, 720-0001, Japan
Gifu Municipal Hospital
Gifu, 500-8513, Japan
Kagoshima University Hospital
Kagoshima, 890-8520, Japan
National Cancer Center Hospital East
Kashiwa-shi, 277-8577, Japan
Hospital of the University of Occupation and Environmental Health
Kitakyushu-shi, 807-8556, Japan
Kobe City Medical Center General Hospital
Kobe, 650-0047, Japan
Japanese Red Cross Nagoya Daini Hospital
Nagoya, 466 8650, Japan
Iuhw Narita Hospital
Narita, 286-8520, Japan
Kindai University Hospital
Osakasayama-shi, 589-8511, Japan
Saitama Medical University Hospital
Saitama, 350-0495, Japan
Osaka University Hospital
Suita-shi, 565-0871, Japan
Juntendo University Hospital
Tokyo, 113-8431, Japan
Mie University Hospital
Tsu, 514-8507, Japan
Yamagata University Hospital
Yamagata, 990-9585, Japan
Amsterdam University Medical Centre
Amsterdam, 1105 AZ, Netherlands
Hospital Rijnstate
Arnhem, 6815 AD, Netherlands
Medisch Spectrum Twente
Enschede, 7512 KZ, Netherlands
Medisch Centrum Leeuwarden
Leeuwarden, 8934 AD, Netherlands
HMC
Leidschendam, 2622BA, Netherlands
Innlandet Hospital Trust
Brumunddal, 02381, Norway
Universitetssykehuset I Trondheim - St. Olavs Hospital
Trondheim, 07006, Norway
Szpital Spec Brzozowiepoland
Brzozów, 36-200, Poland
Pratia Poznan
Katowice, 40-519, Poland
Pratia McM Krakow
Krakow, 30-225, Poland
Sp Zoz Szpital Uniwersytecki
Krakow, 31-501, Poland
Uniwersytet Medyczny W Lodzi - Klinika Hematologii
Lodz, 93-510, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1
Lublin, 20-081, Poland
Specjalistyczny Szpital Onkologiczny
Tomaszów Mazowiecki, 97-200, Poland
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, 02-0781, Poland
Institute of Hematology and Transfusion Medicine
Warsaw, 02-776, Poland
Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego
Wroclaw, 50-367, Poland
Rostov State Medical University
Rostov-on-Don, 344022, Russia
Pavlov First Saint Petersburg State Medical University
Saint Petersburg, 196022, Russia
Pusan National University Yangsan Hospital
Busan, 03181, South Korea
Inje University Busan Paik Hospital
Busan, 47392, South Korea
Dong-A University Hospital
Busan, 49201, South Korea
Pusan National University Yangsan Hospital
Busan, 602-739, South Korea
Kyungpook National University Hospital
Daegu, 41944, South Korea
Daegu Catholic University Medical Center
Daegu, 42472, South Korea
Keimyung University Dongsan Medical Center
Daegu, 42601, South Korea
Chungnam National University
Daejeon, 35015, South Korea
Gacheon University Gil Medical Center
Incheon, 21565, South Korea
Jeonbuk National University Hospital
Jeonju, 54907, South Korea
Seoul National University Hospital
Seoul, 03080, South Korea
Severance Hospital Yonsei University Health System
Seoul, 03722, South Korea
Samsung Medical Center
Seoul, 06351, South Korea
The Catholic University of Korea Yeoido St.Mary'S Hospital
Seoul, 07345, South Korea
Complejo Hospitalario Universitario A Coruna
A Coruña, 15006, Spain
Hospital General Unviersitario de Alicante
Alicante, 03010, Spain
Ico Hospital Germans Trias I Pujol
Badalona, 08916, Spain
Hospital Del Mar
Barcelona, 08003, Spain
Hospital General Universitario Vall D Hebron
Barcelona, 08007, Spain
Hospital de La Santa Creu I Sant Pau
Barcelona, 08041, Spain
Hospital Universitario de Burgos
Burgos, 09006, Spain
Hospital Universitario de Cabuenes
Gijón, 33394, Spain
Institut Catala Doncologia Ico - Hospital Duran I Reynals Location
L'Hospitalet de Llobregat, 08908, Spain
Hospital General Universitario Gregorio Maranon
Madrid, 28007, Spain
Hospital Universitario Ramon Y Cajal
Madrid, 28034, Spain
Fundacion Jimenez Diaz University Hospital
Madrid, 28040, Spain
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Hospital Universitario Quironsalud Madrid
Madrid, 28223, Spain
Hospital Puerta de Hierro
Majadahonda, 28222, Spain
Hospital Universitario Virgen de La Victoria
Málaga, 29010, Spain
Hospital Universitario Virgen de La Arrixaca
Murcia, 30120, Spain
Hospital Son Llatzer
Palma de Mallorca, 07198, Spain
Consorci Hospitalari Parc Tauli de Sabadell
Sabadell, 08208, Spain
Hospital Clinico Universitario de Salamanca
Salamanca, 37007, Spain
Hospital Universitario Marques de Valdecilla
Santander, 39008, Spain
Hospital Universitario Virgen del Rocio Sevilla
Seville, 41005, Spain
Hospital Universitari Mutua Terrassa
Terrassa, 08221, Spain
Hospital Universitario Doctor Peset
Valencia, 46017, Spain
Hospital Universitari I Politecnic La Fe
Valencia, 46026, Spain
Hospital Universitario de Alava
Vitoria-Gasteiz, 01009, Spain
Karolinska University Hospital Solna
Solna, 17164, Sweden
Goetalandsregionen - Uddevalla Sjukhus Us
Uddevalla, 451 53, Sweden
Uppsala Universitet - Akademiska Sjukhuset
Uppsala, 75185, Sweden
University Hospital of Basel Department of Oncology
Basel, 04031, Switzerland
Oncological Institute of Southern Switzerland
Bellinzona, 06500, Switzerland
Inselspital - Universitaetsspital Bern
Bern, 03010, Switzerland
Kantonsspital St. Gallen
Sankt Gallen, 09007, Switzerland
Kantonsspital Winterthur
Winterthur, 08401, Switzerland
Universitatsspital Zurich
Zurich, 08091, Switzerland
E-Da Hospital
Kaohsiung City, 00824, Taiwan
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, 00833, Taiwan
Far Eastern Memorial Hospital
New Taipei City, 00220, Taiwan
China Medical University Hospital
Taichung, 40447, Taiwan
National Cheng Kung University (Ncku) Hospital
Tainan, 00704, Taiwan
National Taiwan University Hospital
Taipei, 00100, Taiwan
Tri Service General Hospital
Taipei, 00114, Taiwan
Institutional Review Board Taipei Veterans General Hospital
Taipei, 11217, Taiwan
Hematology and Medical Oncology Too Foundation Sun Yat Sen Cancer Center
Taipei, 11251, Taiwan
Hacettepe Universitesi Tip Fakultesi Hastanesi
Ankara, 06100, Turkey (Türkiye)
Ankara University Medical Faculty
Ankara, 06590, Turkey (Türkiye)
Acibadem Maslak Hospital
Istanbul, 34457, Turkey (Türkiye)
Communal Non-Profit Enterprise Regional Center of Oncology
Kharkiv, 61070, Ukraine
National Cancer Institute of Ministry of Health
Kyiv, 03022, Ukraine
University Hospitals Birmingham Nhs Foundation Trust
Birmingham, B15 2GW, United Kingdom
Bristol Haematology and Oncology Centre
Bristol, BS2 8ED, United Kingdom
Leicester Royal Infirmary
Leicester, LE1 5WW, United Kingdom
The Royal Marsden Nhs Foundation Trust - Chelsea
London, SW3 6JJ, United Kingdom
The Christie Nhs Foundation Trust Uk
Manchester, M20 4BX, United Kingdom
James Cook University Hospital
Middlesbrough, TS4 3BW, United Kingdom
The Royal Marsden Nhs Foundation Trust - Sutton
Sutton, SM2 5PT, United Kingdom
The Royal Wolverhampton Nhs Trust
Wolverhampton, WV10 0QP, United Kingdom
Related Publications (1)
Sehn LH, Hubel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee HP, Jimenez-Ubieto A, Sancho JM, Kim TM, Domingo Domenech E, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M; inMIND Study team. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. Lancet. 2026 Jan 10;407(10524):133-146. doi: 10.1016/S0140-6736(25)01778-7. Epub 2025 Dec 5.
PMID: 41360064DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Study Director
- Organization
- Incyte Corporation
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Masking Details
- Double Blind
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 17, 2020
First Posted
December 22, 2020
Study Start
April 15, 2021
Primary Completion
February 23, 2024
Study Completion (Estimated)
August 9, 2028
Last Updated
December 22, 2025
Results First Posted
April 4, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
- Access Criteria
- Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency